by Raynovich Rod | May 22, 2023 | 2020-21 Life Science Portfolios, 2021 Rayno Biopharmaceuticals Portfolio
Update-2 5/27/23… Not a great week for healthcare stocks or anything other than IT and the QQQ up 3.59%. S&P 500 Healthcare down 2.93%, Materials down 3.14%, Staples down 3.21%. No debt ceiling deal, recession watch is on. So Karen Firestone, former manager...
by Raynovich Rod | May 15, 2023 | 2020-21 Life Science Portfolios
Update-2…May 19 1015a in early trading, stocks are opening on the green side. Biopharma stocks are trying to firm up after a spate of weakness from the FTC action on the AMGN/Horizon deal: ABBV, GILD, LLY, REGN, RHHBY MRK, VRTX. Update-1 May 17 …Broad...
by Raynovich Rod | May 8, 2023 | 2020-21 Life Science Portfolios, 2021 Rayno Biopharmaceuticals Portfolio
Update-1 5/9/23 Biotech holding up nicely. XBI up 1.48% to $86 handle. CRSP up 14% to $64 handle, NTLA up 2%. GILD in buying range under $80 with 3.76% dividend, FWD PE of 10.9 and strong position in HIV/Aids, viral hepatitis, coronaviruses and emerging portfolio in...
by Raynovich Rod | May 1, 2023 | 2020-21 Life Science Portfolios, Macro
Update-2 5/5….11a EDT Biotech rally continues with strength in SMID stocks: up 1.9% to $85 handle. Gene therapy stocks strong: CRSP EDIT NTLA. IWM up 1.83%to 1750. Spec small caps up big: Acumen (ABOS) up 30% on AD research , VCYT ARKG flat at $29 level. Mid...
by Raynovich Rod | Apr 20, 2023 | 2020-21 Life Science Portfolios, 2021 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Healthcare Stocks-Brief Recap for the Week ending 4/28 A nice steady day holding on to gains with the Russell 2000 up 1.015, the NASDAQ up 0.69%,DOW 30 up 0.8% and the S&P 500 up 0.83%. Life science ETFs for the WEEK: XLV down 0.57% to $133..53, IBB down 2.21%...
by Raynovich Rod | Apr 10, 2023 | 2020-21 Life Science Portfolios, Biopharmaceuticals
4/19/23 1:30 P EDT…Update-3..Added to MedTech weighting in healthcare portfolios: ABT,HOLX, IHI. Talc liabilities weighing on JNJ shares, but sales growth up 5.6%, MedTech bright spot up 7.3%. Abbott (ABT) soars over 7% to $112 level on earnings with recovery...
by Rod Raynovich | Mar 31, 2023 | 2020-21 Life Science Portfolios, Macro
Biotech and Life Science Trades Q1 2023 By the Numbers Leading sectors in Q1 were Tech and Semis.The SPY was up 7% YTD. Small caps beginning to trend up. Healthcare lagging XLV down 5.5% as investors rotate into growth. Despite a strong month and a great finish to the...
by Raynovich Rod | Mar 27, 2023 | 2020-21 Life Science Portfolios, 2021 Rayno Biopharmaceuticals Portfolio
Update-1 3/28/23..Sector rotation continues with energy, materials leading today and healthcare, technology down slightly. Consumer confidence rises to 104.2 despite bank failures. Commodities strong.VikingTherapeutics (VKTX) rose 69% on Phase 1 data for Dua...
by Raynovich Rod | Mar 19, 2023 | 2020-21 Life Science Portfolios, Macro
Update-2 3/24..12;15p ..Biopharma and healthcare stocks rally. Update over weekend. ABBV AMGN BIIB GILD REGN VRTX and UNH and Medtech ISRG MDT…small caps EVH PACB. Update-1 3/22…Away from FEDspeak”. We believe that sm aller cap life science stocks...
by Raynovich Rod | Mar 12, 2023 | 2020-21 Life Science Portfolios, Macro
Small Cap Biotechs Slammed by SVB Collapse Small Cap biotechs have been hit hard and needs time to sort out. Momentum and sentiment in a risk-off mode. Opportunity to assess good stocks for longer term after seeing how they trade. Nothing like a banking crisis to...
